- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03557541
Sardine-enriched Diet for Prevention Type 2 Diabetes
July 18, 2018 updated by: Diana Alicia Diaz Rizzolo, Institut d'Investigacions Biomèdiques August Pi i Sunyer
Sardine-enriched Diet for Prevention Type 2 Diabetes in Elderly and Prediabetic Population
The hypothesis formulated is that 200 g of sardine on a weekly basis will have a favourable impact avoiding the natural development of the pathology due to changes in the biochemical profile, the anthropometrics, inflammatory markers, changes in gut microbiota populations, also in transcriptomics and metabolomics.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
182
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08036
- Diana A Diaz Rizzolo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
63 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- glycaemia between 100-125 md / dL or ≥5.7% HbA1c
Exclusion Criteria:
- treatment with oral antidiabetic drugs
- any nutritional education to prevent T2D
- Suspect or known hypersensitivity to sardine or related fish
- Chronic treatment with oral steroids and / or AINES
- Treatment with oral antidiabetic agents and / or insulin
- Treatment with immunosuppressive drugs
- Diagnosis of active neoplasm
- Diagnosis of HIV or AIDS
- Abnormal liver profile (> 6 times normal values)
- Diagnosis of Acute Psychiatric Sdr
- Presence of serious acute concomitant disease, which it requires more than 7 days of recovery.
- Major cardiovascular event (stroke, myocardial infarction) in the month prior to randomization.
- Any other condition that the investigator considers to be inoperative so that the subject conducts the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control group
|
They received a common T2D-preventive diet
|
Experimental: Sardine group
|
They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
type 2 diabetes new onset
Time Frame: Change from Baseline at 12 months
|
incidence of new diagnosis of type 2 diabetes
|
Change from Baseline at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adiponectin
Time Frame: Change from Baseline at 12 months
|
adiponectin levels
|
Change from Baseline at 12 months
|
quantification of gut microbiota populations
Time Frame: Change from Baseline at 12 months
|
quantification by q-PCR
|
Change from Baseline at 12 months
|
gene expression
Time Frame: Change from Baseline at 12 months
|
relative expression related genes by RT q-PCR (Real Time Quantitative Reverse transcription polymerase chain reaction)
|
Change from Baseline at 12 months
|
metabolomics study of dietary biomarkers and health biomarkers [(1) Fatty acyls, bile acids, steroids and lysoglycerophospholipids, (2) Glycerolipids, glycerophospholipids, sterol lipids and sphingolipids, (3) Amino acids.]
Time Frame: Change from Baseline at 12 months
|
endogenous metabolic profiles of serum samples will be studied using ultra-high performance liquid chromatography - mass spectrometry (UHPLC-MS).
The same unit for measurements [log2 (fold change)]
|
Change from Baseline at 12 months
|
glucose homeostasis
Time Frame: Change from Baseline at 12 months
|
glucose (mg/dl)
|
Change from Baseline at 12 months
|
insulin levels
Time Frame: Change from Baseline at 12 months
|
insulin (mU/L)
|
Change from Baseline at 12 months
|
HOMA-IR (homeostasis model assessment insulin resistance)
Time Frame: Change from Baseline at 12 months
|
insulin resistance index
|
Change from Baseline at 12 months
|
HOMA-B (homeostasis model assessment B cell function)
Time Frame: Change from Baseline at 12 months
|
B cella function
|
Change from Baseline at 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2014
Primary Completion (Actual)
July 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
March 21, 2018
First Submitted That Met QC Criteria
June 4, 2018
First Posted (Actual)
June 15, 2018
Study Record Updates
Last Update Posted (Actual)
July 19, 2018
Last Update Submitted That Met QC Criteria
July 18, 2018
Last Verified
July 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/8863
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on Sardine
-
Spanish Biomedical Research Centre in Diabetes...Completed
-
Brigham and Women's HospitalUnknownPatients Scheduled for Thoracic Surgery/Esophagectomy Will be Enrolled | Persistent Post Surgical Pain